Due to the absence of ER, PR, HER2 expressions, TNBC tumors are unresponsive to hormone therapy or HER2-directed treatment, and TNBC patients also have limited susceptibility to chemotherapy; therefore, TNBC remains the most challenging breast cancer subtype to overcome [8]. Here, ESR1 is linked to breast cancer.